

Press Release

Samsung Active Asset Management Launches KoAct China Biohealthcare Active ETF, Benchmarking the Solactive China Biohealthcare Index

27 January 2026

FRANKFURT AM MAIN – Solactive is pleased to announce its collaboration with Samsung Active Asset Management on the launch of the KoAct China Biohealthcare Active ETF, which uses the Solactive China Biohealthcare Index as a benchmark. The product aims to provide investors with targeted exposure to biohealthcare companies with a strong China and Hong Kong focus, reflecting the growing momentum of healthcare innovation and commercialization across the region.

The biohealthcare sector continues to undergo a rapid transformation as advances in biologics and novel therapies progress from research into broader clinical adoption. In China, the shift from generics toward innovative biologics is supported by structural tailwinds, including an aging population and rising prevalence of chronic diseases, reinforcing long-term demand for healthcare solutions. Regulatory reforms are also supporting innovation by improving review processes and accelerating development timelines, while the growing use of AI, real-world data, and digital tools is enhancing efficiency in drug discovery and development. As China and Hong Kong-listed companies become increasingly integrated into global biotech value chains, the segment is gaining relevance as a diversifying allocation beyond developed markets.

The [Solactive China Biohealthcare Index](#) is designed to reflect this growth story by selecting top 30 eligible companies from the Solactive GBS China All Cap USD Index and the Solactive GBS Hong Kong All Cap Index that are listed on the Hong Kong Stock Exchange and classified in relevant biohealthcare subindustries. Index eligibility requires a minimum share class market capitalization of USD 100 million and an average daily value traded of at least USD 1 million over the three months prior to selection, supporting investability. Constituents are selected by ranking securities by share class market capitalization, and the index applies a market capitalization-based weighting scheme, capping the three largest companies at 10% and all others at 3%, with quarterly rebalancing and monthly reweighting to maintain the intended exposures over time.

The ETF listed on 27 January 2026 on the Korea Exchange (KRX) under the ticker code "[0154H0]".

Timo Pfeiffer, Chief Markets Officer at Solactive, commented: *"Following the successful launch of Samsung Active Asset Management's KoAct US Biohealthcare Active ETF last November, we are pleased to continue our collaboration by providing the benchmark for the new China-focused strategy. Biohealthcare innovation is*

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Dirk Knuetter/Michelle Zhang
PR & Communications
+49 (69) 719 160-311
press@solactive.com

inherently global, and this ETF gives investors access to companies positioned to benefit from China's expanding role in advancing therapies and scaling commercialization."

Hugh Cho, comments: *"China in shifting from a fast follower to a disruptive innovator in biopharma and life sciences and we believe that this shift is secular."*

For more information, please visit:

<http://www.solactive.com>

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Dirk Knuetter/Michelle Zhang
PR & Communications
+49 (69) 719 160-311
press@solactive.com

Note to editors

About Solactive

Solactive is a leading provider of indexing, benchmarking, and calculation solutions for the global investment and trading community. Headquartered in Frankfurt and, with offices in Hong Kong, Toronto, Berlin, Dresden, and Amsterdam, we innovate and disrupt the status quo as the partner of choice for our clients.

The unique blend of our 300 staff's expertise in data, data science, financial markets, and technology enables our clients' continued success through the delivery of a superior experience, unique customization capabilities, and the best value for money available in the industry. With more than 30,000 indices calculated daily, we offer a full suite of solutions, including market-leading ESG and thematic indices.

As of January 2024, Solactive served approximately 500 clients across the world, with approximately US\$300 billion invested in products linked to our indices. Solactive is registered with ESMA as a benchmark administrator and is supervised by the BaFin.

Disclaimer

The information in this document does not constitute tax, legal or investment advice and is not intended as a recommendation for buying or selling securities. Solactive AG and all other companies mentioned in this document are not responsible for the consequences of reliance upon any opinion or statement contained herein or for any omission.

Solactive AG, Platz der Einheit 1, 60327 Frankfurt am Main, Germany. Registered Office: Frankfurt am Main, Registration Court: Amtsgericht Frankfurt am Main, HRB: 79986, USt-IdNr.: DE 255 598 976. Management Board: Steffen Scheuble, Timo Pfeiffer and Nicolas Bös, Head of Supervisory Board: Dr Felix Mühlhäuser.

Solactive AG
German Index Engineering
Platz der Einheit 1
60327 Frankfurt am Main
Germany

Steffen Scheuble
CEO
+49 (69) 719 160-20
steffen.scheuble@solactive.com

Michael Li Ming Nuske, CFA
Team Head Sales APAC
+852 3905 3101
michael.nuske@solactive.com

Dirk Knuetter/Michelle Zhang
PR & Communications
+49 (69) 719 160-311
press@solactive.com